Clinical Trials Browser

Phase 2 × INDUSTRY × ibrutinib × Clear all

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05963074 2026-04-13

TAILOR

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 2 Active not recruiting

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05564052 2025-10-07

VEGA

Phase 2 Completed

36 enrolled 18 charts

Lymphoma, Mantle-Cell

NCT04477486 2025-07-09

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

Phase 2 Completed

13 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT04062448 2025-05-25

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Phase 2 Completed

16 enrolled 14 charts

Waldenstrom Macroglobulinemia

NCT02910583 2024-12-20

Captivate

Phase 2 Completed

323 enrolled 33 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04016805 2023-07-24

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Phase 2 Terminated

41 enrolled 4 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03873493 2022-12-19

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Phase 2 Completed

14 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Leukemia, Prolymphocytic, T-Cell

NCT01109069 2020-05-27

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Phase 2 Completed

199 enrolled 14 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02902965 2020-03-16

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

74 enrolled 20 charts

Multiple Myeloma

NCT01478581 2020-03-10

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

92 enrolled 21 charts

Multiple Myeloma

NCT01980628 2019-10-16

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Phase 2 Completed

63 enrolled 8 charts

Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01980654 2019-04-16

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Phase 2 Completed

80 enrolled 14 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02351037 2018-08-14

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Phase 2 Terminated

36 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01779791 2017-07-18

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Follicular

NCT01325701 2017-03-31

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 2 Completed

78 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02169180 2017-01-24

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Completed

Lymphoma, Mantle-Cell

NCT01599949 2016-06-01

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Phase 2 Completed

Lymphoma, Mantle-Cell

NCT01236391 2015-08-28

PCYC-1104-CA

Phase 2 Completed

115 enrolled 11 charts

Lymphoma, Lymphoma, Mantle-Cell